Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

This study tests whether using a high-tech drug sensitivity test called pharmacoscopy — which directly tests a patient's own cancer cells against dozens of drugs in the lab — can guide treatment decisions for people with relapsed or refractory AML (acute myeloid leukemia), a fast-moving blood cancer that has stopped responding to standard therapies. **You may be eligible if...** - You are between 18 and 70 years old - You have AML that has relapsed (come back) or is refractory (not responding) based on standard criteria - You are healthy enough to receive intensive chemotherapy - You have given written informed consent **You may NOT be eligible if...** - You have a subtype called acute promyelocytic leukemia (APL) - Your AML arose from chronic myeloid leukemia (CML blast crisis) - You are not fit enough for intensive chemotherapy - Your condition is too urgent to wait for the test results - The pharmacoscopy test could not be performed on your sample Talk to your doctor to see if this trial is right for you.